Spironolactone Tablet
Product Images NDC 70518-4447

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 70518-4447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Spironolactone 100mg 70518 4447 00)

Mm1 (Spironolactone 100mg 70518 4447 00)
This is a description of Spironolactone Tablet 100 mg. It comes in a box containing 100 tablets. The tablets are round, white, and scored. The manufacturer is Aurobindo from India. The NDC number for the product is 70518-4447-00. The usual dosage information can be found in the insert. It is recommended to store the medication at 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). It also includes contact information for RemedyRepack Inc. in Indiana, PA for repackaging.*
FDA Label Image

Mm2 (Spironolactone 100mg 70518 4447 01)

Mm2 (Spironolactone 100mg 70518 4447 01)
This is information about a Spironolactone Tablet of 100mg strength. The tablet comes in a qty of 1. It is a round white tablet. The NDC# is 70518-4447-01. The tablet is produced by Aurobindo in India. The usual dosage information can be found in the insert. It should be stored at 20-25°C, with excursions permitted to 15-30°C. Keep out of reach of children. This information is provided for Repackaged By: RemedyRepack Inc.*
FDA Label Image

Figure (Spironolactone Fig1)

Figure (Spironolactone Fig1)
This text appears to contain information related to a clinical study or trial involving Spironolactone and Placebo, with sample sizes of 822 and 841 respectively. The log-rank analysis resulted in a p-value of less than 0.0001, indicating a statistically significant difference between the two groups. The study may have been conducted over a period of 18-24 months.*
FDA Label Image

Fig2 (Spironolactone Fig2)

FDA Label Image

Str1 (Spironolactone Str1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.